The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People’s Republic of China

BACKGROUND: Eli Lilly and the China Primary Health Care Foundation are currently implementing a patient assistance program (PAP) in China, which allows first-line nonsquamous non-small-cell lung cancer (NSCLC) patients who complete four cycles of pemetrexed induction therapy to receive free, continu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Qiang, Hu, Shanlian, Furnback, Wesley E, Guzauskas, Gregory F, Shen, Jiejing, Wang, Bruce CM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302856/
https://www.ncbi.nlm.nih.gov/pubmed/28210100
http://dx.doi.org/10.2147/CEOR.S119818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302856/
https://www.ncbi.nlm.nih.gov/pubmed/28210100
http://dx.doi.org/10.2147/CEOR.S119818

Ejemplares similares